GMA106

Mechanism of action

Gmax describes GMA106 as an \"M-body\": a monoclonal antibody against the GIP receptor (GIPR) with a GLP-1 peptide fused to it, built to engage both the GLP-1 receptor and GIPR at once. The GLP-1 portion is a receptor agonist. Third-party pipeline databases list the antibody portion as a GIPR antagonist, the same antagonist-plus-agonist design as Amgen's maridebart cafraglutide; Gmax's own release says only that it regulates both pathways. No peer-reviewed paper on GMA106's structure or pharmacology was found on PubMed (searched October 4, 2026).

Primary uses

• Obesity (Phase 1 completed)
• Type 2 diabetes and MASH (the maker's stated targets; no trial registered)

Typical dosing

Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Regulatory status

Not approved anywhere. One completed Phase 1 study (NCT05054530, Australia, 2021-2023). Not in Drugs@FDA or the EMA medicines list as of October 4, 2026.

Status as of this entry's last review, October 4, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.

What we checked

GMA106 has no peer-reviewed paper. This section records what can be checked: what the maker says it is, the one registry record, the regulatory status on the date below, and every search we ran.

Identity, computed

GMA106 is an antibody fusion protein, and its amino-acid sequence has not been published, so no formula or mass can be computed. Its structure is known only from the maker's description: an anti-GIPR monoclonal antibody with a GLP-1 peptide fused to it. An earlier version of this entry described it as a GLP-1/FGF21 dual agonist in Phase 2; neither the maker nor the registry supports that, and it was corrected on October 4, 2026.

Regulatory status, read October 4, 2026

Drugs@FDA: 0 records for “GMA106”. EMA medicines list: 0 records for “GMA106”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 84 trials), so a zero here is an absence, not a broken search. Not named on the WADA 2026 and 2027 Prohibited Lists. As a substance with no current approval for human therapeutic use, it falls under section S0 (non-approved substances), which is prohibited at all times; the lists were read on September 27, 2026.

What the maker or sellers claim

Claim, from Gmax Biopharm's November 2021 release: GMA106 is a second-generation antibody therapy for obesity, type 2 diabetes and NASH that acts on both the GLP-1 and GIP receptors, showed superior weight reduction in preclinical studies, and could be combined with Gmax's GLP-1 antibody fusion GMA102. The preclinical data have not been published.

Claim, from the same release: Gmax was preparing applications for Phase 1b/2 trials in China and the United States. As of October 4, 2026, ClinicalTrials.gov lists no such trial.

About the drug class, not this drug

Pairing GLP-1 receptor activation with an antibody against the GIP receptor is the design of Amgen's maridebart cafraglutide, which has its own entry. That drug's trial results are evidence about maridebart cafraglutide only.

The one registry record

NCT05054530 is a randomized, double-blind, placebo-controlled Phase 1 study run at CMAX Clinical Research in Adelaide, Australia, sponsored by Gmax Biopharm Australia. It enrolled 73 healthy, overweight or obese adults between November 2021 and November 2023. The single-dose part planned six cohorts of eight; the maker's release gives those single doses as 4, 10, 20, 40, 60 and 80 mg. The multiple-dose part gave 20, 40 or 80 mg by injection under the skin once a week for 12 weeks. These were trial cohorts testing safety, not doses anyone should use. The record was last updated in January 2024 and lists no results.

What we looked for and did not find

No published paper, no posted trial results, no Phase 2 record, no published sequence or pharmacokinetics, and no FDA or EMA record. A 2024 trade report says Sino Biopharm licensed greater-China rights; we could not read the deal terms and do not rely on them.

References

1. [manufacturer] Gmax Biopharm. "GMAX's GMA106, second generation obesity/T2DM/NASH mAb gives first in human does." Company news release, November 11, 2021. https://www.gmaxbiopharm.com/news_detail/32.html. Read October 4, 2026.
2. [clinicaltrials] ClinicalTrials.gov NCT05054530: Phase 1 randomized, double-blind, placebo-controlled single and multiple ascending dose study of GMA106 in healthy, overweight and obese adults; Gmax Biopharm Australia; 73 enrolled; completed November 17, 2023. Read October 4, 2026.

Related peptides

Guides & tools